HP and metabolic dysfunction-associated steatohepatitis: Several comprehensive studies have already reported an elevated level of fucosylated and sialylated Hp in patients with early-stage HCC compared with patients with cirrhosis in both viral- and non-viral (NASH) etiologies (21, 22, 27–31).